The injection of rAAV-taCasp3 resulted in a significant reduction of CD11c+ microglia (17.1 ± 3.03%) in the ischemic brain 21 days after stroke compared to rAAV-control group (51.15 ± 2.87%) by flow cytometry (Fig. 6D). The gene discussed is ITGAX; the disease is stroke disorder.